Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) has been assigned a $10.00 price target by investment analysts at HC Wainwright in a research report issued on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 37.93% from the company’s previous close.
A number of other research analysts also recently weighed in on TRIL. Zacks Investment Research upgraded Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Thursday, November 23rd. ValuEngine upgraded Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $12.25.
Trillium Therapeutics (NASDAQ:TRIL) opened at $7.25 on Monday. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $95.32, a PE ratio of -1.99 and a beta of 1.85. Trillium Therapeutics has a fifty-two week low of $4.15 and a fifty-two week high of $13.30.
TRADEMARK VIOLATION WARNING: “Trillium Therapeutics (TRIL) PT Set at $10.00 by HC Wainwright” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/12/trillium-therapeutics-tril-pt-set-at-10-00-by-hc-wainwright.html.
Trillium Therapeutics Company Profile
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.